Partnering05

Numab offers its cutting-edge discovery engine to partners looking to develop innovative antibody-based therapeutics with multiple specificities, tailored half-lives, unrivaled potency, and ready to be taken into preclinical and process development. Our disclosed partners are 3SBio/Sunshine Guojian, Boehringer Ingelheim, Eisai, CStone, Ono, Kaken, and Tillotts.

Partners

Boehringer Ingelheim

3SBio / Sunshine Guojian

Eisai Co., Ltd.

CStone Pharmaceuticals

Ono Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Tillotts Pharma AG

Boehringer Ingelheim

In July 2020, Numab and Boehringer Ingelheim announced a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life-changing breakthrough therapies with Numab’s multi-specific antibody platform.  Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each indication. Boehringer Ingelheim received from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.

For more information on Boehringer Ingelheim, please visit: https://www.boehringer-ingelheim.com/

3SBio / Sunshine Guojian

In December 2019, Numab and 3SBio’s subsidiary Sunshine Guojian Pharmaceutical formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific antibodies for the therapy of cancer-based on Numab’s technology platform. Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules emerging from up to three multi-specific antibody programs based on Numab’s R&D platform and has the exclusive licenses to develop and commercialize each of the selected antibody molecules in Greater China territories, including Mainland China, Hong Kong, Macao, and Taiwan, while Numab retains exclusive commercial rights in the rest of the world. Concurrently, Sunshine Guojian has invested CHF15M (approximately USD 15.2M) in Numab’s series B financing. Dr. Zhenping Zhu, MD, Ph.D., President of Research and Development, Chief Scientific Officer of 3SBio, joined Numab’s board of directors.

For more information about 3SBio, please visit: www.3sbio.com

Eisai Co., Ltd.

In October 2019, Numab and Eisai Co., Ltd. announced a research and option agreement to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform. Under the terms of the agreement, Eisai has the option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules that emerge from the joint research collaboration. In exchange, Numab received an upfront payment in addition to research funding and is eligible to receive success fees, milestone payments, and tiered royalties on product sales.

For more information about Eisai, please visit: www.eisai.com

CStone Pharmaceuticals

In May 2019, Numab entered into an exclusive regional licensing agreement for the development and commercialization of its most advanced proprietary asset ND021 with CStone Pharmaceuticals. Pursuant to the terms of the licensing agreement, CStone funds the research and development of ND021, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and serum albumin, up to completion of a first Phase 1b clinical trial. In exchange, CStone obtains exclusive rights to develop and commercialize ND021 in Greater China, including Mainland China, Hong Kong, Macau, and Taiwan, as well as South Korea and Singapore. Numab retains all ND021 rights for the rest of the world. Upon completion of CStone’s funding period, no further financial obligations will be owed by either party.

For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com

Ono Pharmaceutical Co., Ltd.

In March 2017, Numab announced a research and option agreement with Ono Pharmaceutical Co., Ltd. for the identification of a multi-specific antibody candidate in immuno-oncology. The resulting therapeutic program from this initial agreement is called ND023. Under the agreement, Ono obtained an option to acquire intellectual property rights to and exclusive rights to develop ND023 and commercialize the selected lead compound generated in this collaboration. In exchange, Numab receives research funding and up to CHF 258 million in upfront and milestone payments plus tiered single to double-digit royalties on sales.

In March 2020, Numab and Ono expanded their relationship, adding a second multi-specific antibody drug program for the treatment of various cancers to the alliance. The financial terms involved in this second program largely match those of the initial 2017 agreement, essentially doubling the potential commercial value of the relationship for Numab.

For more information, please visit the company’s website at www.ono.co.jp

Kaken Pharmaceutical Co., Ltd.

In June 2017, Numab announced a collaboration and option agreement with Kaken Pharmaceutical Co., Ltd. for the identification of a multi-specific antibody candidate for development in inflammatory disease. Since then Kaken has fully funded the research activities, which gave rise to the therapeutic program ND026. Under the agreement, Kaken has the option to acquire a license and commit to a co-development agreement after the identification of a lead candidate generated by Numab.

For more information, please visit www.kaken.co.jp

 

Tillotts Pharma AG

In June 2015, Numab and Tillotts Pharma AG announced an exclusive global license agreement to develop and commercialize antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). Under the terms of the agreement, Tillotts will develop and commercialize new formulations of the anti-TNF antibody identified as part of Numab’s ND009 program. Numab is eligible to a signing fee and, upon successful development, will receive down-and milestone payments, as well as up to double-digit royalties. With pre-clinical development successfully concluded and ND009 having advanced to IND-ready stage, Tillotts will be seeking a co-development and marketing partner for the U.S. market with a strong interest in working with Tillotts to further develop antibody-based therapies that block TNF-α.

For more information please visit www.tillotts.com.

Newsletter Sign Up

Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept